ABOUT
Changing the oncology paradigm from chemotherapy to chemoprevention, by hacking several signaling pathways to rewrite our cancer odds.
Disrupting carcinogenesis before it highjacks our cells and inhibiting cancer initiation, progression and proliferation.
THE PROBLEM
Based on decades of research and driven by her own high risk of breast and ovarian cancer, Dr Laura Mann Kevehazi, a serial inventor and entrepreneur founded Biocell. The company focuses on R&D of several IP backed drug candidates with the aim to significantly lower the risk of hormone driven malignancy development.
SCIENTIFIC APPROACH
Fundamentally different from the current approach, OBX and OPX are delivering multiple active molecules that simultaneously and comprehensively target carcinogenic pathways at cellular level modulating the microenvironment of hormone driven malignancies.
With evidence of safety and efficacy in human use enabling consistent long term use and increased treatment adherence, OBX and OPX will lead to significant reduction in the risk for breast & prostate cancers compared to current standard of care.
LEAD CANDIDATES
OBX- Breast and Ovarian Chemoprevention Monotherapy
Lifestyle Value based, Non-toxic Therapy for ages 20-80 years old
- Preclinically validated Breast and Ovarian cancer Monotherapy for malignancy prevention – 16 years of remaining patent life
- Exclusively owned IP in the EU, US, JP and CA covering 500m female demographic
- Primary prevention Breast and OvCa (women at high risk) and Secondary (patients in remission to prevent relapse)
- BC Primary Chemoprevention recommended by US Preventive Task force in high-risk demographics. Additional indications in the pipeline
- Quicker route to Phase 2 trials with waived IND requirement (FDA guidelines for botanical drugs #312.22(b))
- Safety record mitigating risk of toxicity failure in later clinical trials, enabling long term/lifestyle preventive therapy in women aged 20-80 years old
- Superior efficacy to old SOC Tamoxifen/Raloxifene, without side effects
- Convenient oral formulation, adequate manufacturing cost, available standardized research samples
- Health insurance coverage highly expected
- Clinical trial pilot POC protocol
Breast Cancer Therapeutics Market size: USD 28.8 billion in 2022 projected to reach USD 73.68 billion by 2032 with a compound annual growth rate (CAGR) of 9.9%
OPX - Prostate Cancer Chemoprevention & Fertility Improvement
Lifestyle Value based, Non-toxic Therapy for men 30-80 years old
- Prostate Cancer Chemoprevention & Fertility Improvement Monotherapy – 16 years of patent life
- Exclusively owned IP in the EU, US, JP covering >400m male demographic
- Quicker route to Phase 2 trials with no IND requirement (FDA guidelines for botanical drugs #312.22(b))
- Safety record mitigating risk of toxicity failure in later clinical trials, enabling long term preventive therapy adherence
- Superior to old SOC Finasteride/Dudasteride, without side effects
- Primary chemoprevention (men at high risk) and Secondary (patients in remission to prevent relapse) prevention
- Fertility market; significant sperm improvement across multiple parameters with growing fertility market assessed at 5B
- Convenient oral formulation, adequate manufacturing cost, available standardized research samples
- Health insurance coverage highly expected
- Clinical trial pilot POC protocol
Prostate Cancer Therapeutics Market USD 13.7 Billion in 2023 expected to reach USD 28.5 Billion by 2032 (Data Horizon Research)
Lancet Commission on Prostate Cancer (April 2024): Prostate Cancer cases expected to double from 1.4million 2020 to 2.9 million by 2040- main increase in East Asia.